Photo Release -- Nasdaq Welcomes Cellectis SA (Nasdaq: CLLS) to The Nasdaq Stock Market


NEW YORK, March 25, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Cellectis SA (Nasdaq:CLLS) commenced on The Nasdaq Stock Market on March 25, 2015.

A photo accompanying this release is available at http://resource.globenewswire.com/Resource/Download/1615fe01-5705-4231-9e12-3cb7b5bff6c0

 Cellectis is a pioneering gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).  Cellectis is dedicated to developing new types of cancer therapies based on these cells. The Company’s gene-editing technologies give the ability to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves. 

“Cellectis is innovating in the field of cancer treatment by harnessing the immune system to target and eradicate cancers,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq.  “We are excited to welcome Cellectis to the Nasdaq family and congratulate them on their initial public offering.”

By listing with Nasdaq, Cellectis joins some of the world’s largest and most revolutionary healthcare companies. Nasdaq is the exchange of choice to 72 percent of healthcare companies and 57 percent of European companies listed in the U.S. Markets.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.1 trillion and more than 10,000 corporate clients. To learn more, visit http://nasdaq.com/ambition or http://business.nasdaq.com

NDAQG



            
Cellectis Cellectis

Tags


Contact Data